about
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatmentRituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patientsThrombopoietic agents in immune thrombocytopenia.[Immune thrombocytopenia--pathophysiology and treatment].Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura.Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP).Health-related quality of life after deep vein thrombosis.A qualitative study of patient experiences of decentralized acute healthcare services.Health-related quality of life after pulmonary embolism: a cross-sectional study.A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.New oral anticoagulants--a review.New anticoagulants in combination with antiplatelet agents.Scoring Systems for Postthrombotic Syndrome.General practitioners' perspectives on referring patients to decentralized acute health care.Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial.Risk of cardiovascular events and pulmonary hypertension following splenectomy - a Danish population-based cohort study from 1996-2012.Evaluating patient experiences in decentralised acute care using the Picker Patient Experience Questionnaire; methodological and clinical findings.Pain and bleeding associated with trephine biopsy.Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.[Hairy cell leukemia treated with cladribine].[Primary myelofibrosis--pathogenesis, diagnosis and treatment].Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.Quality of life after pulmonary embolism: first cross-cultural evaluation of the pulmonary embolism quality-of-life (PEmb-QoL) questionnaire in a Norwegian cohort.Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis.Diagnostic scales for the post-thrombotic syndrome.Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.Antidotbehandling ved bruk av direktevirkende antikoagulasjonsmidler.Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome.Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771).
P50
Q26991661-2B13608E-B275-4028-9A45-A9AB09C8B0B6Q28255301-2139CE4F-6704-4C72-8183-0A83E38D65BBQ33390632-0CFF3DE7-5FB1-4811-9BCF-0A697ED1B199Q33392691-22BEBA60-8BAA-49B9-AAAA-D05585CABA9EQ33396730-8C65BA72-2182-45BE-9855-386B25B39695Q33397092-080CA71D-9ACD-48AA-9EFE-0409DF7CF9A8Q33400949-66EAF844-BBCD-4392-AB06-FEFCC063C39CQ33412896-2F99603F-A60A-45A6-8D3D-FCB83F604E8EQ33414722-BDBDCF45-AFAF-49B6-974D-CEDEBA44BCE5Q33420238-9D0E5223-D719-4570-9E2D-14E0EEDCFD3CQ33428564-3BED789C-6055-4605-8E4B-2667EC30F8D3Q33436570-7C52D254-728D-4975-B2CB-CBE5539670F9Q37159143-DE969EEA-FE31-4227-8A09-D7F525AFC2E6Q37281921-EB84EC37-FB45-44BA-8092-2A1114E44C93Q37454250-38060E7C-7019-4EDC-A145-2FB5A48CCD78Q37562899-04A2E2BF-19B0-42B5-B910-E71EED61DAFDQ38148436-A33D7BF2-25E8-44B5-9E0F-437B2F3AA425Q38978713-2D53AC2A-3FAD-471A-ACD0-889A05853D3AQ39282622-F219C3E3-FD72-417A-8C48-A18D6C770E27Q39471263-8D4FFD96-1F3D-4A55-B5A0-3CD1B852C609Q39513246-682144B9-A521-4261-8E26-FED2CE570E3BQ40016363-58EDC968-B197-4306-A0A7-4399A2CCF2D9Q40176999-5CB023A7-2A07-4B73-8D8D-0CE2BD2E6BBCQ42049446-B692AB12-7639-44E9-9561-4310C88D6E72Q42219703-58A0E4D5-5668-4F15-8B1E-158EA15D3F10Q42628839-86A9B233-7FB7-4613-A36C-8613A4E79F8AQ44013555-906F149B-3425-4D64-AAD8-82C04796AE49Q44206164-A60E531E-EF25-41F0-B8BD-5D95642CDDFAQ46047574-AFDBAE91-FACA-4F5F-9629-FC2C725732E8Q47614945-F3940C4E-D99F-487F-BA1C-01D5F4A33289Q48298790-A6888E7C-A7DC-467D-AB53-122F2F7CACADQ48692208-FA85D86B-5847-4FC4-B364-197D38A6C030Q50066207-AD4472DF-1E6C-4C06-9A50-3672490CD812Q50087873-B5996475-9A6F-473E-A2FB-01C6C26D668AQ50144731-6647F8AC-A414-4A24-AC28-E464068EE65AQ50738138-B45DF5EB-7606-4369-9788-B5ED73FA0381Q52345031-187FADF2-DA2A-4ADD-A0E9-6F534FF6633CQ52732629-60B85B51-8BC1-45C0-9EFC-DD7BEDB42F87Q53184198-E5D930A0-8099-4D4B-9886-89A19D0FF235Q53226595-8BE0E304-AF03-4BC3-B3B5-C837481DF119
P50
description
Noors onderzoeker
@nl
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Waleed Ghanima
@ast
Waleed Ghanima
@en
Waleed Ghanima
@es
Waleed Ghanima
@nl
Waleed Ghanima
@sl
type
label
Waleed Ghanima
@ast
Waleed Ghanima
@en
Waleed Ghanima
@es
Waleed Ghanima
@nl
Waleed Ghanima
@sl
prefLabel
Waleed Ghanima
@ast
Waleed Ghanima
@en
Waleed Ghanima
@es
Waleed Ghanima
@nl
Waleed Ghanima
@sl
P106
P21
P27
P31
P496
0000-0003-2225-6165
P569
1964-01-01T00:00:00Z